Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1CNS 1

Conditions

Obesity 1Craniopharyngioma 1

Interventions

Vitamin D 2Tirzepatide 2Metformin 2licogliflozin 1indole-3-carbinol 1bupropion hydrochloride, naltrexone hydrochoride drug combination 1Tablets 1Specimen Handling 1Resistance Training 1Progestins 1Pregabalin 1Orlistat 1Organizational Objectives 1Omeprazole 1Observation 1Naltrexone 1Ketorolac 1Exergaming 1Exercise 1Exenatide 1Diet, Plant-Based 1Dexmedetomidine 1Dalteparin 1Counseling 1Cholecalciferol 1Calcium Citrate 1Calcium Carbonate 1Calcitriol 1CKD732 1Bupropion 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Obesity × CKD732 × Clear all
NCT02063295 2016-07-18

An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury

Zafgen, Inc.

Phase 2 Completed
14 enrolled
CNSOther

Craniopharyngioma, Obesity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡